CA3006746C - Solid dispersions comprising a sgc stimulator - Google Patents
Solid dispersions comprising a sgc stimulator Download PDFInfo
- Publication number
- CA3006746C CA3006746C CA3006746A CA3006746A CA3006746C CA 3006746 C CA3006746 C CA 3006746C CA 3006746 A CA3006746 A CA 3006746A CA 3006746 A CA3006746 A CA 3006746A CA 3006746 C CA3006746 C CA 3006746C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- solid dispersion
- dispersion
- disease
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007962 solid dispersion Substances 0.000 title claims abstract description 223
- 229940127296 soluble guanylate cyclase stimulator Drugs 0.000 title description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 547
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 100
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 191
- 229920000642 polymer Polymers 0.000 claims description 104
- 208000035475 disorder Diseases 0.000 claims description 97
- 201000010099 disease Diseases 0.000 claims description 94
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 63
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 63
- 230000036541 health Effects 0.000 claims description 42
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 35
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 35
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 35
- 206010020772 Hypertension Diseases 0.000 claims description 33
- 206010019280 Heart failures Diseases 0.000 claims description 30
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 26
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 18
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 17
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 17
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 13
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 claims description 13
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 claims description 13
- 201000006370 kidney failure Diseases 0.000 claims description 13
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 13
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 13
- 238000001694 spray drying Methods 0.000 claims description 11
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 10
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 10
- 208000017169 kidney disease Diseases 0.000 claims description 10
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 9
- 208000020832 chronic kidney disease Diseases 0.000 claims description 9
- 229920001577 copolymer Polymers 0.000 claims description 8
- 239000000945 filler Substances 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 8
- 208000015658 resistant hypertension Diseases 0.000 claims description 8
- 238000009825 accumulation Methods 0.000 claims description 6
- 239000007884 disintegrant Substances 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 201000002793 renal fibrosis Diseases 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 230000000750 progressive effect Effects 0.000 claims description 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 208000034189 Sclerosis Diseases 0.000 claims description 3
- 230000008021 deposition Effects 0.000 claims description 3
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 3
- 208000037816 tissue injury Diseases 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 abstract description 34
- CYSJNTQNMDWAJV-UHFFFAOYSA-N praliciguat Chemical compound C1=C(F)C(NCC(O)(C(F)(F)F)C(F)(F)F)=NC(C2=NN(CC=3C(=CC=CC=3)F)C(C3=NOC=C3)=C2)=N1 CYSJNTQNMDWAJV-UHFFFAOYSA-N 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 description 236
- 239000003826 tablet Substances 0.000 description 140
- 239000000203 mixture Substances 0.000 description 68
- 239000000243 solution Substances 0.000 description 67
- 238000003860 storage Methods 0.000 description 67
- 238000000034 method Methods 0.000 description 64
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- 239000007787 solid Substances 0.000 description 53
- 238000000634 powder X-ray diffraction Methods 0.000 description 50
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 48
- 241000282472 Canis lupus familiaris Species 0.000 description 47
- 238000006243 chemical reaction Methods 0.000 description 45
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 32
- 238000010922 spray-dried dispersion Methods 0.000 description 32
- 238000002360 preparation method Methods 0.000 description 31
- 208000002815 pulmonary hypertension Diseases 0.000 description 31
- 238000011282 treatment Methods 0.000 description 31
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 30
- 239000002002 slurry Substances 0.000 description 29
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 28
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 28
- 239000002552 dosage form Substances 0.000 description 27
- 238000004128 high performance liquid chromatography Methods 0.000 description 25
- 239000011777 magnesium Substances 0.000 description 23
- 239000002274 desiccant Substances 0.000 description 22
- 239000012065 filter cake Substances 0.000 description 22
- 238000004519 manufacturing process Methods 0.000 description 22
- 239000000463 material Substances 0.000 description 22
- 239000007921 spray Substances 0.000 description 21
- 238000004090 dissolution Methods 0.000 description 20
- 238000000386 microscopy Methods 0.000 description 20
- 238000000113 differential scanning calorimetry Methods 0.000 description 18
- 230000002685 pulmonary effect Effects 0.000 description 18
- 229920006395 saturated elastomer Polymers 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 238000000576 coating method Methods 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 17
- 229920002785 Croscarmellose sodium Polymers 0.000 description 16
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 16
- 208000007536 Thrombosis Diseases 0.000 description 16
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 16
- 208000015114 central nervous system disease Diseases 0.000 description 16
- 229960001681 croscarmellose sodium Drugs 0.000 description 16
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 239000012530 fluid Substances 0.000 description 15
- 238000005550 wet granulation Methods 0.000 description 15
- 208000024827 Alzheimer disease Diseases 0.000 description 14
- 239000005430 Avicel DG Substances 0.000 description 14
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 14
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 14
- 229920003072 Plasdone™ povidone Polymers 0.000 description 14
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 14
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 14
- 239000001506 calcium phosphate Substances 0.000 description 14
- 206010012601 diabetes mellitus Diseases 0.000 description 14
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 14
- 229940038472 dicalcium phosphate Drugs 0.000 description 14
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 208000006011 Stroke Diseases 0.000 description 13
- 239000004815 dispersion polymer Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- 229920003084 Avicel® PH-102 Polymers 0.000 description 12
- 208000005189 Embolism Diseases 0.000 description 12
- 208000005615 Interstitial Cystitis Diseases 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 230000001684 chronic effect Effects 0.000 description 12
- 238000002425 crystallisation Methods 0.000 description 12
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 12
- 201000001881 impotence Diseases 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 11
- 230000000747 cardiac effect Effects 0.000 description 11
- 239000011248 coating agent Substances 0.000 description 11
- 208000014674 injury Diseases 0.000 description 11
- 230000001568 sexual effect Effects 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 201000001320 Atherosclerosis Diseases 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 229920001903 high density polyethylene Polymers 0.000 description 10
- 239000004700 high-density polyethylene Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 9
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 208000010228 Erectile Dysfunction Diseases 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000036772 blood pressure Effects 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 238000005469 granulation Methods 0.000 description 9
- 230000003179 granulation Effects 0.000 description 9
- 239000005297 pyrex Substances 0.000 description 9
- 208000006029 Cardiomegaly Diseases 0.000 description 8
- 208000032928 Dyslipidaemia Diseases 0.000 description 8
- 208000018262 Peripheral vascular disease Diseases 0.000 description 8
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 239000008186 active pharmaceutical agent Substances 0.000 description 8
- 230000008025 crystallization Effects 0.000 description 8
- 230000003511 endothelial effect Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 208000028867 ischemia Diseases 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 7
- 101150041968 CDC13 gene Proteins 0.000 description 7
- 206010021143 Hypoxia Diseases 0.000 description 7
- 208000017170 Lipid metabolism disease Diseases 0.000 description 7
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 7
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 7
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 208000019425 cirrhosis of liver Diseases 0.000 description 7
- 208000010877 cognitive disease Diseases 0.000 description 7
- 238000009506 drug dissolution testing Methods 0.000 description 7
- 238000007908 dry granulation Methods 0.000 description 7
- 230000004064 dysfunction Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 208000019423 liver disease Diseases 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 230000002093 peripheral effect Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 208000037803 restenosis Diseases 0.000 description 7
- 201000002859 sleep apnea Diseases 0.000 description 7
- 230000002792 vascular Effects 0.000 description 7
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 6
- 206010006482 Bronchospasm Diseases 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 206010011796 Cystitis interstitial Diseases 0.000 description 6
- 206010012289 Dementia Diseases 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- 206010057671 Female sexual dysfunction Diseases 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 6
- 208000019693 Lung disease Diseases 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 208000032109 Transient ischaemic attack Diseases 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 6
- 230000007885 bronchoconstriction Effects 0.000 description 6
- 238000007906 compression Methods 0.000 description 6
- 230000006835 compression Effects 0.000 description 6
- 230000004761 fibrosis Effects 0.000 description 6
- 208000016354 hearing loss disease Diseases 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 208000005069 pulmonary fibrosis Diseases 0.000 description 6
- 238000001953 recrystallisation Methods 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- 201000010875 transient cerebral ischemia Diseases 0.000 description 6
- 206010003694 Atrophy Diseases 0.000 description 5
- 206010007559 Cardiac failure congestive Diseases 0.000 description 5
- 208000000059 Dyspnea Diseases 0.000 description 5
- 206010013975 Dyspnoeas Diseases 0.000 description 5
- 208000021663 Female sexual arousal disease Diseases 0.000 description 5
- 208000035150 Hypercholesterolemia Diseases 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 208000001145 Metabolic Syndrome Diseases 0.000 description 5
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 5
- 208000022873 Ocular disease Diseases 0.000 description 5
- 208000028017 Psychotic disease Diseases 0.000 description 5
- 208000012322 Raynaud phenomenon Diseases 0.000 description 5
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 5
- 230000037007 arousal Effects 0.000 description 5
- 208000037849 arterial hypertension Diseases 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 230000037444 atrophy Effects 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 208000020016 psychiatric disease Diseases 0.000 description 5
- 238000009490 roller compaction Methods 0.000 description 5
- 239000012798 spherical particle Substances 0.000 description 5
- 230000002537 thrombolytic effect Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 4
- 208000010482 CADASIL Diseases 0.000 description 4
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 4
- 208000003417 Central Sleep Apnea Diseases 0.000 description 4
- 208000033221 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 206010011878 Deafness Diseases 0.000 description 4
- 206010052337 Diastolic dysfunction Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 4
- 208000012661 Dyskinesia Diseases 0.000 description 4
- 206010048554 Endothelial dysfunction Diseases 0.000 description 4
- 208000000289 Esophageal Achalasia Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 description 4
- 208000010412 Glaucoma Diseases 0.000 description 4
- 208000016621 Hearing disease Diseases 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 206010020852 Hypertonia Diseases 0.000 description 4
- 206010020880 Hypertrophy Diseases 0.000 description 4
- 208000024934 IgG4-related mediastinitis Diseases 0.000 description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 4
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 4
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 4
- 208000019022 Mood disease Diseases 0.000 description 4
- 208000001089 Multiple system atrophy Diseases 0.000 description 4
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 206010030136 Oesophageal achalasia Diseases 0.000 description 4
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 4
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 4
- 201000001068 Prinzmetal angina Diseases 0.000 description 4
- 206010067284 Pulmonary arteriopathy Diseases 0.000 description 4
- 201000001880 Sexual dysfunction Diseases 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 208000008253 Systolic Heart Failure Diseases 0.000 description 4
- 208000001435 Thromboembolism Diseases 0.000 description 4
- 201000004810 Vascular dementia Diseases 0.000 description 4
- 201000000621 achalasia Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 229940045348 brown mixture Drugs 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 208000010118 dystonia Diseases 0.000 description 4
- 230000008694 endothelial dysfunction Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 238000009474 hot melt extrusion Methods 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 4
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 4
- 238000013101 initial test Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 229960004502 levodopa Drugs 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 229920002689 polyvinyl acetate Polymers 0.000 description 4
- 239000011118 polyvinyl acetate Substances 0.000 description 4
- 208000028173 post-traumatic stress disease Diseases 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 231100000872 sexual dysfunction Toxicity 0.000 description 4
- 208000007056 sickle cell anemia Diseases 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000008279 sol Substances 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- 239000011877 solvent mixture Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 208000004746 Atrophic Vaginitis Diseases 0.000 description 3
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 description 3
- 206010071445 Bladder outlet obstruction Diseases 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 208000026151 Chronic thromboembolic pulmonary hypertension Diseases 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 3
- 206010011953 Decreased activity Diseases 0.000 description 3
- 208000003037 Diastolic Heart Failure Diseases 0.000 description 3
- 208000007530 Essential hypertension Diseases 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010020853 Hypertonic bladder Diseases 0.000 description 3
- 206010021639 Incontinence Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000029523 Interstitial Lung disease Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 3
- 206010029279 Neurogenic bladder Diseases 0.000 description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 3
- 206010061876 Obstruction Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 3
- 206010063985 Phytosterolaemia Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 208000010378 Pulmonary Embolism Diseases 0.000 description 3
- 206010039710 Scleroderma Diseases 0.000 description 3
- 208000002227 Sitosterolemia Diseases 0.000 description 3
- 206010071436 Systolic dysfunction Diseases 0.000 description 3
- 239000004809 Teflon Substances 0.000 description 3
- 229920006362 Teflon® Polymers 0.000 description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 description 3
- 238000002399 angioplasty Methods 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 3
- 235000013539 calcium stearate Nutrition 0.000 description 3
- 239000008116 calcium stearate Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 150000003278 haem Chemical class 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 208000006575 hypertriglyceridemia Diseases 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011976 maleic acid Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 208000020629 overactive bladder Diseases 0.000 description 3
- 210000003899 penis Anatomy 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 206010036596 premature ejaculation Diseases 0.000 description 3
- 210000001147 pulmonary artery Anatomy 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- WXXSNCNJFUAIDG-UHFFFAOYSA-N riociguat Chemical compound N1=C(N)C(N(C)C(=O)OC)=C(N)N=C1C(C1=CC=CN=C11)=NN1CC1=CC=CC=C1F WXXSNCNJFUAIDG-UHFFFAOYSA-N 0.000 description 3
- 208000012201 sexual and gender identity disease Diseases 0.000 description 3
- 208000015891 sexual disease Diseases 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 230000009424 thromboembolic effect Effects 0.000 description 3
- 230000001732 thrombotic effect Effects 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 230000009529 traumatic brain injury Effects 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- OOMBRKGIWITBLL-UHFFFAOYSA-N (2-fluorophenyl)methylhydrazine Chemical compound NNCC1=CC=CC=C1F OOMBRKGIWITBLL-UHFFFAOYSA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 208000004611 Abdominal Obesity Diseases 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 2
- 208000017194 Affective disease Diseases 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 206010002153 Anal fissure Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010059245 Angiopathy Diseases 0.000 description 2
- 206010058079 Anomalous pulmonary venous connection Diseases 0.000 description 2
- 208000016583 Anus disease Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 200000000007 Arterial disease Diseases 0.000 description 2
- 206010003225 Arteriospasm coronary Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000036640 Asperger disease Diseases 0.000 description 2
- 201000006062 Asperger syndrome Diseases 0.000 description 2
- 206010003805 Autism Diseases 0.000 description 2
- 208000020706 Autistic disease Diseases 0.000 description 2
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 208000004990 Cardiorenal syndrome Diseases 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 206010065941 Central obesity Diseases 0.000 description 2
- 208000033935 Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 208000027104 Chemotherapy-Related Cognitive Impairment Diseases 0.000 description 2
- 206010008748 Chorea Diseases 0.000 description 2
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 208000029147 Collagen-vascular disease Diseases 0.000 description 2
- 208000002330 Congenital Heart Defects Diseases 0.000 description 2
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010011903 Deafness traumatic Diseases 0.000 description 2
- 208000024254 Delusional disease Diseases 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 206010056340 Diabetic ulcer Diseases 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 208000014094 Dystonic disease Diseases 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 208000009531 Fissure in Ano Diseases 0.000 description 2
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 description 2
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 206010021133 Hypoventilation Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010021518 Impaired gastric emptying Diseases 0.000 description 2
- 206010022562 Intermittent claudication Diseases 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 2
- 208000009829 Lewy Body Disease Diseases 0.000 description 2
- 201000002832 Lewy body dementia Diseases 0.000 description 2
- 208000008771 Lymphadenopathy Diseases 0.000 description 2
- 206010025219 Lymphangioma Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010057672 Male sexual dysfunction Diseases 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000002805 Mediastinal fibrosis Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 229920003091 Methocel™ Polymers 0.000 description 2
- 208000011682 Mitral valve disease Diseases 0.000 description 2
- 208000018526 Narcotic-Related disease Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 2
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 2
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 2
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 2
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 2
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 2
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 208000027089 Parkinsonian disease Diseases 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 208000028361 Penetrating Head injury Diseases 0.000 description 2
- 206010034487 Pericarditis constrictive Diseases 0.000 description 2
- 206010061340 Peripheral embolism Diseases 0.000 description 2
- 206010034576 Peripheral ischaemia Diseases 0.000 description 2
- 208000012202 Pervasive developmental disease Diseases 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920003075 Plasdone™ K-29/32 polymer Polymers 0.000 description 2
- 206010036631 Presenile dementia Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 208000031467 Pulmonary capillary hemangiomatosis Diseases 0.000 description 2
- 206010037457 Pulmonary vasculitis Diseases 0.000 description 2
- 208000014777 Pulmonary venoocclusive disease Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000003782 Raynaud disease Diseases 0.000 description 2
- 201000008206 Renpenning syndrome Diseases 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 2
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 2
- 206010040642 Sickle cell anaemia with crisis Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 206010050207 Skin fibrosis Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 2
- 208000007718 Stable Angina Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 2
- 208000007814 Unstable Angina Diseases 0.000 description 2
- 208000009325 Variant Angina Pectoris Diseases 0.000 description 2
- 208000032594 Vascular Remodeling Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 206010049644 Williams syndrome Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229940081664 adempas Drugs 0.000 description 2
- 208000013228 adenopathy Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 208000033571 alveolar capillary dysplasia with misalignment of pulmonary veins Diseases 0.000 description 2
- 238000005576 amination reaction Methods 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 206010002906 aortic stenosis Diseases 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 208000029560 autism spectrum disease Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 208000010217 blepharitis Diseases 0.000 description 2
- 208000015294 blood coagulation disease Diseases 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000011132 calcium sulphate Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 208000016886 cerebral arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 description 2
- 208000011142 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 Diseases 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000024825 childhood disintegrative disease Diseases 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- 208000012601 choreatic disease Diseases 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 230000009852 coagulant defect Effects 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 208000028831 congenital heart disease Diseases 0.000 description 2
- 208000018631 connective tissue disease Diseases 0.000 description 2
- 208000000839 constrictive pericarditis Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000007887 coronary angioplasty Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 231100000895 deafness Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- GOWQBFVDZPZZFA-UHFFFAOYSA-N diethyl 2-fluoropropanedioate Chemical compound CCOC(=O)C(F)C(=O)OCC GOWQBFVDZPZZFA-UHFFFAOYSA-N 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 230000009429 distress Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- FMVJYQGSRWVMQV-UHFFFAOYSA-N ethyl propiolate Chemical compound CCOC(=O)C#C FMVJYQGSRWVMQV-UHFFFAOYSA-N 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 208000001288 gastroparesis Diseases 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- -1 glidants Substances 0.000 description 2
- 229940049654 glyceryl behenate Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 231100000888 hearing loss Toxicity 0.000 description 2
- 230000010370 hearing loss Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000004024 hepatic stellate cell Anatomy 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 208000018875 hypoxemia Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000021156 intermittent vascular claudication Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000005461 lubrication Methods 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 208000027061 mild cognitive impairment Diseases 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000003041 necroinflammatory effect Effects 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 208000002851 paranoid schizophrenia Diseases 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 208000030761 polycystic kidney disease Diseases 0.000 description 2
- 208000007232 portal hypertension Diseases 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 201000011461 pre-eclampsia Diseases 0.000 description 2
- 230000036316 preload Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 201000008312 primary pulmonary hypertension Diseases 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 208000037813 pulmonary venous hypertension Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 201000004409 schistosomiasis Diseases 0.000 description 2
- 208000022610 schizoaffective disease Diseases 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 208000037812 secondary pulmonary hypertension Diseases 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000035946 sexual desire Effects 0.000 description 2
- 238000009491 slugging Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical group [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- 201000009032 substance abuse Diseases 0.000 description 2
- 231100000736 substance abuse Toxicity 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 230000003956 synaptic plasticity Effects 0.000 description 2
- 230000002885 thrombogenetic effect Effects 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 208000014001 urinary system disease Diseases 0.000 description 2
- 210000002229 urogenital system Anatomy 0.000 description 2
- 208000037820 vascular cognitive impairment Diseases 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- UXYRXGFUANQKTA-UHFFFAOYSA-N 1,2-oxazole-3-carboxylic acid Chemical compound OC(=O)C=1C=CON=1 UXYRXGFUANQKTA-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- NYZSKEULTVZUAW-UHFFFAOYSA-N 2,2-bis(trifluoromethyl)oxirane Chemical compound FC(F)(F)C1(C(F)(F)F)CO1 NYZSKEULTVZUAW-UHFFFAOYSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- ZBMRKNMTMPPMMK-UHFFFAOYSA-N 2-amino-4-[hydroxy(methyl)phosphoryl]butanoic acid;azane Chemical compound [NH4+].CP(O)(=O)CCC(N)C([O-])=O ZBMRKNMTMPPMMK-UHFFFAOYSA-N 0.000 description 1
- XSFVAQRSZSENGO-UHFFFAOYSA-N 3-benzyl-2h-indazole Chemical compound N1N=C2C=CC=CC2=C1CC1=CC=CC=C1 XSFVAQRSZSENGO-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- DUFGYCAXVIUXIP-UHFFFAOYSA-N 4,6-dihydroxypyrimidine Chemical compound OC1=CC(O)=NC=N1 DUFGYCAXVIUXIP-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 102100026288 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 3 Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000011345 Duchenne and Becker muscular dystrophy Diseases 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- 206010014513 Embolism arterial Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000785919 Homo sapiens Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 3 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010024119 Left ventricular failure Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 108010079943 Pentagastrin Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010039163 Right ventricular failure Diseases 0.000 description 1
- 201000004239 Secondary hypertension Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000029901 Sexual arousal disease Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 208000011963 Substance-induced psychotic disease Diseases 0.000 description 1
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 206010071018 Urogenital atrophy Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001405 anti-neuronal effect Effects 0.000 description 1
- 230000003206 anti-remodeling effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 238000013172 carotid endarterectomy Methods 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 208000020020 complex sleep apnea Diseases 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 201000002545 drug psychosis Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 201000011384 erythromelalgia Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000009795 fibrotic process Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000036044 hypoxaemia Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229910001959 inorganic nitrate Inorganic materials 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000027928 long-term synaptic potentiation Effects 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 201000006646 mixed sleep apnea Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000002644 neurohormonal effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000001797 obstructive sleep apnea Diseases 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000010421 oxidative-nitrosative stress Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical class C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000018052 penile erection Effects 0.000 description 1
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 1
- 229960000444 pentagastrin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- JSPCTNUQYWIIOT-UHFFFAOYSA-N piperidine-1-carboxamide Chemical compound NC(=O)N1CCCCC1 JSPCTNUQYWIIOT-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000011471 prostatectomy Methods 0.000 description 1
- 201000004240 prostatic hypertrophy Diseases 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000003304 psychophysiological effect Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 229960000529 riociguat Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035936 sexual power Effects 0.000 description 1
- 230000036332 sexual response Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 239000008275 solid aerosol Substances 0.000 description 1
- 239000008259 solid foam Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 208000037905 systemic hypertension Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 206010046947 vaginismus Diseases 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 238000003963 x-ray microscopy Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562260910P | 2015-11-30 | 2015-11-30 | |
| US62/260,910 | 2015-11-30 | ||
| US201662359440P | 2016-07-07 | 2016-07-07 | |
| US62/359,440 | 2016-07-07 | ||
| PCT/US2016/063312 WO2017095697A1 (en) | 2015-11-30 | 2016-11-22 | Solid dispersions comprising a sgc stimulator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3006746A1 CA3006746A1 (en) | 2017-06-08 |
| CA3006746C true CA3006746C (en) | 2024-01-30 |
Family
ID=57590822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3006746A Active CA3006746C (en) | 2015-11-30 | 2016-11-22 | Solid dispersions comprising a sgc stimulator |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20190269619A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3383372B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6952707B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102841419B1 (cg-RX-API-DMAC7.html) |
| CN (4) | CN108883071A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016364976B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018011154B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3006746C (cg-RX-API-DMAC7.html) |
| EA (1) | EA201891315A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL259493B (cg-RX-API-DMAC7.html) |
| MX (3) | MX389961B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017095697A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017216429B2 (en) * | 2016-02-01 | 2022-10-06 | Cyclerion Therapeutics, Inc. | Use of sGC stimulators for the treatment of Nonalcoholic Steatohepatitis (NASH) |
| EA201990237A1 (ru) * | 2016-07-07 | 2019-08-30 | Сайклерион Терапьютикс, Инк. | Новые способы получения стимуляторов растворимой гуанилатциклазы |
| MX382762B (es) * | 2016-07-07 | 2025-03-13 | Cyclerion Therapeutics Inc | Procesos novedosos para preparacion de estimuladores de guanilato ciclasa soluble. |
| WO2019055859A1 (en) | 2017-09-14 | 2019-03-21 | Ironwood Pharmaceuticals, Inc. | TREATMENT OF METABOLIC SYNDROME BY SGC STIMULATOR |
| KR20250048609A (ko) | 2018-01-10 | 2025-04-09 | 사이클리온 테라퓨틱스, 인크. | 가용성 구아닐레이트 시클라제 자극제의 제조를 위한 신규 방법 및 중간체 |
| WO2019161534A1 (en) * | 2018-02-22 | 2019-08-29 | Ironwood Pharmaceuticals, Inc. | Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators |
| WO2019172420A1 (ja) * | 2018-03-09 | 2019-09-12 | 協和発酵キリン株式会社 | 医薬組成物 |
| KR102755855B1 (ko) * | 2018-07-30 | 2025-01-15 | 가부시키가이샤 리코 | 입자의 제조 방법, 및 이 방법에 의해 제조된 입자 및 의약 |
| JP7503781B2 (ja) * | 2018-07-30 | 2024-06-21 | 株式会社リコー | 粒子の製造方法、並びに、それにより製造された粒子及び医薬 |
| US12409140B2 (en) * | 2019-09-23 | 2025-09-09 | Bionomics Limited | Therapeutic formulations and uses thereof |
| AU2020372900A1 (en) | 2019-10-29 | 2022-05-26 | Cyclerion Therapeutics, Inc. | Treatment of diabetic nephropathy with an sGC stimulator |
| KR20230121867A (ko) * | 2020-12-18 | 2023-08-21 | 유씨비 바이오파마 에스알엘 | 무정형 고체 분산체 |
| WO2023009710A1 (en) | 2021-07-28 | 2023-02-02 | Cyclerion Therapeutics, Inc. | Treatment of hfpef in post-menopausal women with an sgc stimulator |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0901786T3 (da) * | 1997-08-11 | 2007-10-08 | Pfizer Prod Inc | Faste farmaceutiske dispersioner med foröget biotilgængelighed |
| DE60039379D1 (de) * | 1999-02-10 | 2008-08-21 | Pfizer Prod Inc | Pharmazeutische feste Dispersionen |
| KR20140011366A (ko) * | 2011-03-08 | 2014-01-28 | 잘리커스 파마슈티컬즈 리미티드 | 고체 분산체 제형 및 그의 이용방법 |
| US9309235B2 (en) * | 2012-09-18 | 2016-04-12 | Ironwood Pharmaceuticals, Inc. | SGC stimulators |
| EA033168B1 (ru) * | 2013-03-15 | 2019-09-30 | Сайклерион Терапьютикс, Инк. | СТИМУЛЯТОРЫ sGC |
| WO2015106268A1 (en) * | 2014-01-13 | 2015-07-16 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
-
2016
- 2016-11-22 AU AU2016364976A patent/AU2016364976B2/en active Active
- 2016-11-22 CA CA3006746A patent/CA3006746C/en active Active
- 2016-11-22 WO PCT/US2016/063312 patent/WO2017095697A1/en not_active Ceased
- 2016-11-22 CN CN201680077389.7A patent/CN108883071A/zh active Pending
- 2016-11-22 MX MX2018006422A patent/MX389961B/es unknown
- 2016-11-22 US US15/780,212 patent/US20190269619A1/en not_active Abandoned
- 2016-11-22 CN CN202310714714.8A patent/CN116942616A/zh active Pending
- 2016-11-22 JP JP2018547255A patent/JP6952707B2/ja active Active
- 2016-11-22 EP EP16816486.1A patent/EP3383372B1/en active Active
- 2016-11-22 CN CN202310714716.7A patent/CN116637076A/zh active Pending
- 2016-11-22 EA EA201891315A patent/EA201891315A1/ru unknown
- 2016-11-22 CN CN202310714725.6A patent/CN116637077A/zh active Pending
- 2016-11-22 KR KR1020187018204A patent/KR102841419B1/ko active Active
- 2016-11-22 BR BR112018011154-6A patent/BR112018011154B1/pt active IP Right Grant
-
2018
- 2018-05-21 IL IL259493A patent/IL259493B/en unknown
- 2018-05-24 MX MX2022001656A patent/MX2022001656A/es unknown
- 2018-05-24 MX MX2022001655A patent/MX2022001655A/es unknown
-
2021
- 2021-09-28 JP JP2021157646A patent/JP7277534B2/ja active Active
-
2022
- 2022-02-03 IL IL290338A patent/IL290338B2/en unknown
-
2023
- 2023-05-08 JP JP2023076655A patent/JP7641320B2/ja active Active
- 2023-12-29 US US18/400,392 patent/US20240293324A1/en not_active Abandoned
-
2024
- 2024-05-16 US US18/665,775 patent/US20250017862A1/en not_active Abandoned
-
2025
- 2025-02-14 US US19/054,072 patent/US20250255821A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250255821A1 (en) | Solid dispersions comprising a sgc stimulator | |
| JP5017115B2 (ja) | ４−（４−（３−（４−クロロ−３−トリフルオロメチルフェニル）ウレイド）−３−フルオロフェノキシ）ピリジン−２−カルボン酸を含んでなる過剰増殖性疾患の治療のための新規薬剤組成物 | |
| EP1949902B1 (en) | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR | |
| US20210228489A1 (en) | Compositions for treating cystic fibrosis | |
| WO2001095912A1 (fr) | Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph | |
| AU2015362728B2 (en) | Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide | |
| JP2009542647A (ja) | メマンチン医薬組成物 | |
| US12318487B2 (en) | Solid tablet dosage form of ridinilazole | |
| WO2023213878A1 (en) | Solid tablet dosage form of ridinilazole | |
| HK1261747A1 (en) | Solid dispersions comprising a sgc stimulator | |
| HK1261747B (en) | Solid dispersions comprising a sgc stimulator | |
| TW202110453A (zh) | 嘧啶基胺基－吡唑化合物之修飾釋放調配物及治療方法 | |
| KR20240155526A (ko) | 엔잘루타마이드를 포함하는 무정형 고체 분산체, 그를 포함하는 경구 투여용 약제학적 제제 | |
| EA043018B1 (ru) | Твердые дисперсии, содержащие стимулятор sgc, для применения в качестве лекарственного средства |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20211119 |
|
| EEER | Examination request |
Effective date: 20211119 |
|
| EEER | Examination request |
Effective date: 20211119 |
|
| EEER | Examination request |
Effective date: 20211119 |
|
| EEER | Examination request |
Effective date: 20211119 |
|
| EEER | Examination request |
Effective date: 20211119 |
|
| EEER | Examination request |
Effective date: 20211119 |
|
| EEER | Examination request |
Effective date: 20211119 |